Peter J. Zimetbaum

Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY.

Beth Israel Deaconess Medical Center provides medical services. It offers patient care, biomedical research, teaching, and community services. It also provides organ transplantation, breast cancer care, and cardiac surgery services. The company was founded in 1896 and is headquartered in Boston, MA.

The Baim Institute for Clinical Research manages clinical trial data in a range of therapeutic areas for commercial, academic, and scientific purposes. The firm engages in the design, management, and data analysis of clinical trials in the U.S. and internationally. It offers clinical CRO services that include trial design, project management, site management and monitoring, statistical analysis, medical monitoring and oversight, clinical endpoint event identification and adjudication and medical writing services; and data management, including electronic data capture services. The company was founded by Donald S. Baim and Richard E. Kuntz in 1993 and is headquartered in Boston, MA.